The body leaves a chemical trace. The question now is whether medicine will listen.
For generations, millions of women have carried the weight of an invisible illness, waiting nearly a decade for a diagnosis that required surgery to confirm. Researchers at the University of Edinburgh have now identified a distinct hormonal signature in the blood of endometriosis patients — one that could compress that nine-year ordeal into months. The discovery, rooted in an overlooked class of androgens, does not merely promise a faster test; it reframes the disease itself, suggesting that endometriosis is shaped by hormonal pathways medicine has long neglected to examine.
- A 95% diagnostic accuracy rate in initial testing signals that a reliable, non-invasive blood test for endometriosis may finally be within reach.
- The current nine-year average wait for diagnosis is not a medical inevitability but a systemic failure — one that allows disease progression, compounding pain, and narrowing lives for one in ten women globally.
- Edinburgh researchers found elevated levels of 11-ketotestosterone and other adrenal androgens in endometriosis patients, opening a biological door that prior research had largely left unopened.
- The team is actively seeking industry partners through the university's commercialization arm, but larger trials across diverse populations stand between this discovery and clinical reality.
- Beyond diagnosis, the androgen connection hints at unexplored therapeutic pathways — the blood test may be the immediate prize, but the deeper scientific reframing could prove more transformative still.
For nearly a decade, women with endometriosis move through appointments, imaging studies, and mounting pain before surgery finally confirms what their bodies have long signaled. A team at the University of Edinburgh believes they have found a way to collapse that timeline to months — with nothing more than a blood test.
Endometriosis occurs when tissue similar to the uterine lining grows where it shouldn't, inflaming surrounding tissue and leaving scar in its wake. Diagnosis has historically required surgery, because no blood marker or imaging signature has been reliable enough to stand alone. Scientists have long focused on estrogen and progesterone as the disease's drivers, but the Edinburgh team looked elsewhere — at 11-oxygenated androgens, a class of so-called male hormones produced by the adrenal glands and largely unexplored in this context.
Analyzing blood samples from 159 women with confirmed endometriosis and 57 without, researchers found a distinct hormonal fingerprint in those with the condition — elevated levels of 11-ketotestosterone and related androgens. The signature correctly identified more than 95 percent of patients with the disease, suggesting a biological marker precise enough to become a clinical tool.
The stakes are significant. Endometriosis affects one in ten women globally, yet it has been chronically underfunded and under-researched. The nine-year diagnostic delay in the UK reflects a broader pattern of dismissal. Without diagnosis, treatment remains out of reach, and the disease advances unchecked. A blood test would not cure the condition, but it would move diagnosis from the operating room to the laboratory.
The team is now working with Edinburgh Innovations to find industry partners for development, though larger trials across diverse populations are essential before any test reaches clinical practice. Dr. Douglas Gibson, who led the research, framed the finding as a fundamental shift — endometriosis is not simply an estrogen-driven disorder but a condition shaped by multiple hormonal pathways. That reframing opens doors not only for diagnosis but potentially for treatment. The blood test is the immediate prize; the deeper insight may prove more valuable still.
For nearly a decade, women with endometriosis wait. They move through years of appointments, imaging studies, and mounting pain before a surgeon finally confirms what their bodies have been telling them all along. A team at the University of Edinburgh believes they may have found a way to collapse that timeline from nine years to months—with nothing more than a blood test.
The condition itself is straightforward enough in its mechanics: tissue similar to the uterine lining grows where it shouldn't, responding to hormonal signals, inflaming surrounding tissue, and leaving scar tissue in its wake. What has made endometriosis so difficult to pin down is that diagnosis has required surgery. There is no blood marker, no imaging signature reliable enough to stand alone. So patients suffer through years of uncertainty while the disease progresses untreated.
Scientists have long understood that endometriosis is driven by the female hormones estrogen and progesterone. But the Edinburgh researchers decided to look elsewhere—at androgens, the so-called male hormones that circulate in female bodies too, and specifically at a group called 11-oxygenated androgens produced by the adrenal glands. This was territory largely unexplored in endometriosis research. When they analyzed blood samples from 159 women with confirmed endometriosis and 57 without, they found something striking: those with the condition carried a distinct hormonal fingerprint, marked by elevated levels of 11-ketotestosterone and other androgens in this overlooked category.
The signature was precise enough to matter. Using this hormone pattern to distinguish between patients with and without endometriosis, the researchers correctly identified more than 95 percent of those who had the disease. That accuracy, in an initial study, suggests something real—a biological marker that could be measured, standardized, and turned into a clinical tool.
Endometriosis touches one in ten women and people assigned female at birth globally, yet it has been chronically underfunded and under-researched. The nine-year diagnostic delay in the UK is not an outlier; it reflects a broader pattern of dismissal and neglect. Without a diagnosis, treatment remains out of reach. The disease advances. Pain compounds. Lives narrow. A simple blood test would not solve the underlying condition, but it would transform access to care—moving diagnosis from the operating room to the laboratory, from years to months.
The team is now working with Edinburgh Innovations, the university's commercialization arm, to find industry partners willing to develop this into an actual diagnostic product. Larger trials will be essential. The findings need validation across more diverse populations before any test reaches clinical practice. But the principle is established: the body leaves a chemical trace. The question now is whether the medical system will finally listen.
Dr. Douglas Gibson, who led the research, framed the finding as a fundamental shift in how endometriosis is understood—not simply as an estrogen-driven disorder, but as a condition shaped by multiple hormonal pathways. That reframing opens new doors not just for diagnosis but for treatment. If androgens play a role in endometriosis, then modulating them might offer a therapeutic avenue no one has fully explored. The blood test is the immediate prize. The deeper insight may prove more valuable still.
Notable Quotes
Traditionally seen as an estrogen-driven disorder, our research challenges this view by showing different androgen levels in the condition.— Dr. Douglas Gibson, University of Edinburgh Centre for Reproductive Health
A reliable, non-surgical diagnostic test is much needed, long-awaited, and could help drive down diagnosis times to just a few months.— Emma Cox, CEO of Endometriosis UK
The Hearth Conversation Another angle on the story
Why has endometriosis diagnosis taken so long to crack? It's not a rare disease.
Because diagnosis requires surgery. There's no blood marker, no scan that definitively says yes or no. So patients cycle through years of tests that don't answer the question, while the disease progresses untreated.
And this new finding—the androgen signature—that's something no one was really looking at before?
Exactly. Endometriosis research has focused almost entirely on estrogen and progesterone. Androgens were overlooked, even though they circulate in female bodies and clearly play a role. This team simply asked a different question.
The 95 percent accuracy in their initial study—is that enough to move toward a clinical test?
It's promising, but it's a small study. They tested 159 women with endometriosis and 57 without. Before any test reaches patients, you need larger trials across different populations, different ages, different backgrounds. The biology has to hold up.
What changes if this works? Beyond the obvious—faster diagnosis?
Everything downstream changes. Treatment can start years earlier. Disease progression slows. Women don't spend a decade in pain wondering if they're imagining it. And researchers now have a new angle on what drives the condition, which could lead to entirely new treatments.
Who benefits most from this, if it becomes real?
The women who've already waited nine years benefit least—they're past diagnosis. The real impact is on the next generation. And on the millions globally who are still waiting, still being told their pain isn't real because there's no test to prove it is.